Moscow has suggested to Tokyo that a green corridor be created for pharmaceutical companies, Russian Deputy Prime Minister Olga Golodets said ahead of a meeting with Japan’s Minister of Economy, Trade and Industry Hiroshige Seko on Saturday.
“We have suggested that the so-called green corridor be created for pharmaceutical companies, as we want to ease the access to the Russian market for Japanese companies,” she said, adding that talks on that matter have been held with Hitachi, Ltd.
The meeting also involves Russian Economic Development Minister Maksim Oreshkin.
Moscow and Tokyo have been have been boosting economic cooperation based on the Japanese prime minister’s eight-point plan. The document stipulates that Russia and Japan should strengthen relations in the energy sphere, small and medium-size business, the industrialization of Russia’s Far East, as well as expand exports.
Source: TASS
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.
